Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity

Vaccine

Volumn 28, Issue 41, 2010, Pages 6675-6683

  Hu, Biliang ^a   Dai, Bingbing ^a   Wang, Pin ^a  

^a University of Southern California ^*  (United States)

Author keywords

Antigen specific immune responses; Integration deficient lentiviral vectors; Targeting dendritic cells

Indexed keywords

ASPARTIC ACID; INTEGRASE; INTEGRATION DEFICIENT LENTIVIRUS VECTOR; LENTIVIRUS VECTOR; OVALBUMIN; UNCLASSIFIED DRUG; VALINE; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG TARGETING; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; SAFETY; SINDBIS VIRUS;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; GENETIC VECTORS; GP100 MELANOMA ANTIGEN; HIV INTEGRASE; LENTIVIRUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; POINT MUTATION; THYMOMA; TRANSDUCTION, GENETIC; TRANSGENES; VIRUS INTEGRATION;

EID: 77956469094     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.012     Document Type: Article

References (43)

1. Pfeifer A., Verma I.M. Gene therapy: promises and problems. Annu Rev Genom Hum G 2001, 2:177-211.
2. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
3. Kootstra N.A., Verma I.M. Gene therapy with viral vectors. Annu Rev Pharmacol 2003, 43:413-439.
4. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
5. Figdor C.G., de Vries I.J.M., Lesterhuis W.J., Melief C.J.M. Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10:475-480.
6. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
7. Dullaers M., Thielemans K. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J Gene Med 2006, 8:3-17.
8. Schroers R., Chen S.Y. Lentiviral transduction of human dendritic cells. Methods Mol Biol 2004, 246:451-459.
9. Esslinger C., Romero P., MacDonald H.R. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum Gene Ther 2002, 13:1091-1100.
10. Kim J.H., Majumder N., Lin H., Watkins S., Falo L.D., You Z. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther 2005, 16:1255-1266.
11. Dullaers M., Van Meirvenne S., Heirman C., Straetman L., Bonehill A., Aerts J.L., et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 2006, 13:630-640.
12. Lemiale F., Korokhov N. Lentiviral vectors for HIV disease prevention and treatment. Vaccine 2009, 27:3443-3449.
13. Yang L., Yang H., Rideout K., Cho T., Joo K.I., Ziegler L., et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008, 26:326-334.
14. Montini E., Cesana D., Schmidt M., Sanvito F., Ponzoni M., Bartholomae C., et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006, 24:687-696.
15. Bokhoven M., Stephen S.L., Knight S., Gevers E.F., Robinson I.C., Takeuchi Y., et al. Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol 2009, 83:283-294.
16. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
17. Nienhuis A.W., Dunbar C.E., Sorrentino B.P. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 2006, 13:1031-1049.
18. Wanisch K., Yanez-Munoz R.J. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 2009, 17:1316-1332.
19. Philpott N.J., Thrasher A.J. Use of nonintegrating lentiviral vectors for gene therapy. Hum Gene Ther 2007, 18:483-489.
20. Philippe S., Sarkis C., Barkats M., Mammeri H., Ladroue C., Petit C., et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 2006, 103:17684-17689.
21. Yanez-Munoz R.J., Balaggan K.S., MacNeil A., Howe S.J., Schmidt M., Smith A.J., et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006, 12:348-353.
22. Apolonia L., Waddington S.N., Fernandes C., Ward N.J., Bouma G., Blundell M.P., et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 2007, 15:1947-1954.
23. Bayer M., Kantor B., Cockrell A., Ma H., Zeithaml B., Li X., et al. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol Ther 2008, 16:1968-1976.
24. Negri D.R., Michelini Z., Baroncelli S., Spada M., Vendetti S., Buffa V., et al. Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 2007, 15:1716-1723.
25. Coutant F., Frenkiel M.P., Despres P., Charneau P. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 2008, 3:e3973.
26. Karwacz K., Mukherjee S., Apolonia L., Blundell M.P., Bouma G., Escors D., et al. Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 2009, 83:3094-3103.
27. Hu B., Yang H., Dai B., Tai A., Wang P. Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum Gene Ther 2009, 20:1652-1664.
28. Leavitt A.D., Robles G., Alesandro N., Varmus H.E. Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol 1996, 70:721-728.
29. Lois C., Hong E.J., Pease S., Brown E.J., Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002, 295:868-872.
30. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998, 72:8463-8471.
31. Geraerts M., Willems S., Baekelandt V., Debyser Z., Gijsbers R. Comparison of lentiviral vector titration methods. BMC Biotechnol 2006, 6:34.
32. Butler S.L., Hansen M.S., Bushman F.D. A quantitative assay for HIV DNA integration in vivo. Nat Med 2001, 7:631-634.
33. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., Carbone F.R. T cell receptor antagonist peptides induce positive selection. Cell 1994, 76:17-27.
34. Barnden M.J., Allison J., Heath W.R., Carbone F.R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998, 76:34-40.
35. Vargas J., Gusella G.L., Najfeld V., Klotman M.E., Cara A. Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 2004, 15:361-372.
36. Saenz D.T., Loewen N., Peretz M., Whitwam T., Barraza R., Howell K.G., et al. Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol 2004, 78:2906-2920.
37. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2:251-262.
38. Dutton R.W., Bradley L.M., Swain S.L. T cell memory. Annu Rev Immunol 1998, 16:201-223.
39. Perricone M.A., Claussen K.A., Smith K.A., Kaplan J.M., Piraino S., Shankara S., et al. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol Ther 2000, 1:275-284.
40. Dai B., Yang L., Yang H., Hu B., Baltimore D., Wang P. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci USA 2009, 106:20382-20387.
41. Zhou T., Chen Y., Hao L., Zhang Y. DC-SIGN and immunoregulation. Cell Mol Immunol 2006, 3:279-283.
42. Matsuno K., Ezaki T., Kudo S., Uehara Y. A life stage of particle-laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver to the draining lymph. J Exp Med 1996, 183:1865-1878.
43. Gaur M., Leavitt A.D. Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not eliminate provirus formation. J Virol 1998, 72:4678-4685.